CAR-T Cell Therapy Full Process Explained: 10 Things Patients Must Know

Introduction

When conventional chemotherapy or targeted drugs fail, many patients with hematologic malignancies hear a new term—CAR-T cell therapy. This therapy, hailed as a "living drug," is not a simple infusion but a systematic project involving multidisciplinary collaboration. According to 2023 data from the Center for International Blood and Marrow Transplant Research (CIBMTR), more than 30,000 patients worldwide have received CAR-T therapy, with complete remission rates of 60%-80% for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. However, behind the high success rates lie complex procedures and stringent management. For patients preparing for or considering this therapy, understanding the entire process is the first step. This article, from a Chinese patient's perspective, outlines 10 key points of CAR-T treatment to help you navigate it with confidence.

1. Pre-treatment Evaluation: Not All Patients Are Suitable

CAR-T is not a panacea. The primary requirement is a confirmed diagnosis of a B-cell tumor positive for targets such as CD19 or BCMA, with failure or relapse after at least two lines of standard therapy. Evaluation includes bone marrow function, cardiac, hepatic, and renal function, infection status, and tumor burden. For example, if peripheral blood blast percentage exceeds 25% or there is central nervous system involvement, cytoreduction or local treatment is needed first. Additionally, age is not typically a hard limit, but performance status (ECOG score 0-2) and organ reserve are hard criteria. It is recommended that patients bring all medical records to an experienced medical institution for multidisciplinary consultation, avoiding blind pursuit of new therapies.

2. Cell Collection: One Apheresis, Manageable Risks

Once treatment is confirmed, the first step is collecting the patient's own T cells. The process is similar to blood donation, using a cell separator for apheresis, typically taking 2-4 hours to collect 50-200 ml of cell suspension. This is completed in an outpatient or inpatient setting, with main risks being hypocalcemia, blood volume fluctuations, or hematoma at the puncture site. Certain immunosuppressants (e.g., steroids, cyclosporine) must be stopped at least 1 week before collection to ensure T-cell viability. The required collection is generally CD3+ cells ≥1×10^9; if insufficient, a second collection may be needed. Patients should not be overly anxious, as doctors will monitor vital signs throughout.

3. Manufacturing Wait Period: Managing the 2-4 Week "Gap Window"

This is the most overlooked stage. Cells are sent to a GMP-compliant laboratory for genetic modification and expansion, during which bridging therapy is needed to control the tumor. Common strategies include low-dose chemotherapy, targeted drugs, or radiotherapy, as determined by the physician. Infection is the biggest concern during this phase, as lymphopenia leads to weakened immunity. Patients are advised to minimize outings, maintain oral and skin hygiene, and avoid raw or cold foods. Psychological stress may also increase; meditation or family companionship can help. The wait period typically lasts 14-28 days, but if cell expansion fails (incidence about 1%-5%), a backup plan must be activated, so it is essential to confirm with your doctor whether a "safety net" plan exists.

4. Lymphodepleting Chemotherapy: Making Room for CAR-T Cells

Three to five days before infusion, patients receive lymphodepleting chemotherapy, commonly with cyclophosphamide and fludarabine. The goal is to eliminate regulatory T cells and residual immune cells, creating space for CAR-T cell homing and expansion. This chemotherapy dose is lower than standard regimens but may still cause myelosuppression, nausea, or fever. Close monitoring of blood counts and liver and kidney function is required, with red blood cell or platelet transfusions if necessary. Stronger lymphodepletion is not always better; excessive intensity increases infection risk, while insufficient intensity affects efficacy—individualized regimens are key.

5. Infusion: One Intravenous Infusion, Lifelong Memory

The infusion process is similar to a blood transfusion, usually completed within 10-30 minutes, though some patients may take 30-60 minutes. Cells should be infused promptly after thawing, with close observation for allergic reactions. After infusion, CAR-T cells expand in the body and attack tumors, a process that may last several weeks. Patients are then transferred to a monitored ward and hospitalized for at least 2 weeks of observation to manage potential cytokine release syndrome (CRS) or neurotoxicity. The infusion itself is painless, but subsequent reactions vary, so psychological preparation is needed.

6. Cytokine Release Syndrome: Be Vigilant, Not Panicked

CRS is the most common complication, occurring in about 50%-90% of patients, presenting as high fever, hypotension, hypoxia, or even multi-organ failure. Grading ranges from grade 1 (fever only) to grade 4 (requiring mechanical ventilation or dialysis). Mild CRS can be managed with antipyretics and fluids, while moderate to severe cases require tocilizumab (IL-6 receptor antagonist) or corticosteroids. Early recognition is crucial; nurses assess temperature and blood pressure every 2-4 hours. Patients and families should learn to record symptom changes and report promptly, avoiding self-medication with antipyretics that may mask the condition.

7. Neurotoxicity: Possible but Often Reversible

About 20%-60% of patients experience immune effector cell-associated neurotoxicity syndrome (ICANS), with symptoms ranging from headache, tremor to aphasia, or seizures. Most occur 1-5 weeks after infusion and may last days to weeks. Management includes antiepileptic drugs (e.g., levetiracetam) and brain imaging; severe cases may require intubation for airway protection. The good news is that most ICANS is reversible, but neurologist involvement is needed. Patients should avoid driving and operating machinery until symptoms fully resolve and EEG is normal.

8. Long-term Follow-up: The First 3 Months Are Golden

At days 30, 90, and 180 post-infusion, imaging and bone marrow examinations are needed to assess efficacy and residual disease. After complete remission, monitoring of B-cell recovery and immunoglobulin levels is still necessary, as CAR-T may cause prolonged hypogammaglobulinemia, requiring regular immunoglobulin infusions. Additionally, blood counts, liver and kidney function, and viral reactivation (EBV, CMV) should be monitored. Some patients may develop secondary malignancies, but the incidence is extremely low (<0.1%). It is recommended to establish a follow-up calendar and maintain regular contact with the primary physician, not interrupting follow-up due to symptom improvement.

9. Costs and Insurance: Plan Ahead to Avoid Interruptions

In China, the total cost of CAR-T therapy is approximately 1.2-1.5 million RMB (including cell manufacturing and hospitalization), currently not covered by national medical insurance, but some commercial insurance or local supplemental insurance may cover it. Meijiakang provides a cost estimator service to help assess out-of-pocket expenses. Additionally, participating in clinical trials may reduce some costs. It is essential to confirm reimbursement details with the hospital and insurance company before treatment to avoid delays due to financial issues mid-treatment.

10. Psychological and Life Support: Rebuilding Confidence, Returning to Daily Life

Successful treatment is not the endpoint. Many patients face fatigue, memory issues, or mood swings after discharge. It is recommended to join patient communities, engage in rehabilitation exercises, and gradually resume social activities. No special dietary restrictions are needed, but a high-protein, easily digestible diet should be ensured. Returning to work or study should be discussed with a doctor, generally advising 3-6 months of rest. Family support is crucial; family members should learn basic care skills and accompany patients through the "gap window."

Recommendations for International Patients

For patients seeking CAR-T therapy in China from overseas, especially from Europe or the United States, three points should be noted: First, prepare and translate pathology reports, imaging films, and previous treatment records in advance, as domestic hospitals typically require English versions or notarized Chinese translations; second, plan a stay of at least 6-8 weeks, as the entire process includes evaluation, collection, manufacturing, and post-infusion observation; third, consider visas and medical insurance. Our international patient services provide one-stop support, including remote consultations, translation assistance, and accommodation arrangements. In summary, CAR-T is not a simple infusion but a journey requiring comprehensive management. Rational evaluation, thorough preparation, and trust in the team are essential to maximize benefits.